The round was led by Novartis Venture Fund and Apple Tree Partners with participation from previous investors Versant Ventures and Domain Associates. In conjunction with the funding, David McIntyre and Sami Hamade of Apple Tree Partners and Steven Weinstein of Novartis Venture Fund, respectively, will join ROX Medical’s Board of Directors.
The company intends to use the funds to initiate a U.S. pivotal clinical trial of the ROX Coupler therapy for patients in need of alternative solutions for uncontrolled hypertension.
Led by CEO Rodney Brenneman, Rox is a medical device company advancing pioneering an innovative interventional vascular device therapy for uncontrolled hypertension. It develops the ROX Medical Coupler, a small stent-like device that creates a connection between the artery and vein in the upper leg with a minimally invasive outpatient procedure.
The company has CE Mark approval and published a landmark randomized controlled study in The Lancet, January 2015.
FinSMEs
06/09/2016